Company intelligence / Profile preview

Estrellita Pharmaceuticals

Emeryville, California, United States

Ownership: Private
Development stage: Other

Overview

EB103 achieved complete response in first patient dosed in Phase 1/2 STARLIGHT-1 trial for B-cell lymphomas with favorable safety profile; no serious treatment-related AEs observed.

Therapeutic areas: OncologyImmunology
Modalities: T cell therapyCAR-T cell therapy
Industry: Biotech

Partnerships

Eureka Therapeutics, Inc.Imugene Limited

Beyond the preview

Go deeper on Estrellita Pharmaceuticals.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Estrellita Pharmaceuticals.

Explore the full profile